Zilovertamab vedotin
Phase 2TerminatedDevelopment Stage
Triple-negative Breast Cancer
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
Oct 7, 2020 → Jun 12, 2023
About Zilovertamab vedotin
Zilovertamab vedotin is a phase 2 stage product being developed by Merck for Triple-negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04504916. Target conditions include Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC.
Hype Score Breakdown
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06395103 | Phase 1/2 | Recruiting |
| NCT05144841 | Phase 2 | Active |
| NCT04504916 | Phase 2 | Terminated |
| NCT03833180 | Phase 1 | Completed |
Competing Products
20 competing products in Triple-negative Breast Cancer